Ekso Bionics Holdings, Inc. (EKSO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EKSO Revenue Growth
Revenue Breakdown (FY 2023)
EKSO's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
By Geography
EKSO Revenue Analysis (2014–2025)
As of May 8, 2026, Ekso Bionics Holdings, Inc. (EKSO) generated trailing twelve-month (TTM) revenue of $11.6 million, reflecting significant decline in growth of -36.6% year-over-year. The most recent quarter (Q1 2026) recorded $2.1 million in revenue, down 31.8% sequentially.
Looking at the longer-term picture, EKSO's 5-year compound annual growth rate (CAGR) stands at +7.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $18.3 million in 2023.
Revenue diversification analysis shows EKSO's business is primarily driven by Product (77%), Service (15%), and Subscription (5%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IRBT (-33.1% YoY), CYBR (+36.0% YoY), and ATAI (+811.8% YoY), EKSO has underperformed the peer group in terms of revenue growth. Compare EKSO vs IRBT →
EKSO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EKSOCurrent | $12M | -36.6% | +7.6% | -104.1% | |
 IRBT | $682M | -33.1% | -10.9% | -15.1% | |
 CYBR | $1.4B | +36.0% | +24.0% | -7.7% | |
 ATAI | $308,000 | +811.8% | - | -33341.2% | |
 MYO | $41M | +6.7% | +40.1% | -35.2% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% |
EKSO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $12.8M | -28.6% | $6.8M | 53.5% | $-13,326,000 | -104.1% |
| 2024 | $17.9M | -1.9% | $9.5M | 53.1% | $-10,460,000 | -58.4% |
| 2023 | $18.3M | +41.6% | $9.1M | 49.7% | $-15,112,000 | -82.7% |
| 2022 | $12.9M | +14.8% | $6.2M | 48.1% | $-15,556,000 | -120.5% |
| 2021 | $11.2M | +26.6% | $6.7M | 60.0% | $-13,828,000 | -123.0% |
| 2020 | $8.9M | -36.2% | $5.1M | 57.1% | $-12,858,000 | -144.8% |
| 2019 | $13.9M | +22.8% | $6.8M | 48.6% | $-16,639,000 | -119.6% |
| 2018 | $11.3M | +54.1% | $4.3M | 38.0% | $-27,030,000 | -238.5% |
| 2017 | $7.4M | -48.3% | $2.1M | 28.1% | $-31,612,000 | -429.9% |
| 2016 | $14.2M | +64.2% | $2.9M | 20.7% | $-27,586,000 | -194.0% |
See EKSO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EKSO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EKSO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEKSO — Frequently Asked Questions
Quick answers to the most common questions about buying EKSO stock.
Is EKSO's revenue growth accelerating or slowing?
EKSO revenue declined -36.6% year-over-year, contrasting with the 5-year CAGR of +7.6%. TTM revenue fell to $12M. This reverses the prior growth trend.
What is EKSO's long-term revenue growth rate?
Ekso Bionics Holdings, Inc.'s 5-year revenue CAGR of +7.6% reflects the variable expansion pattern. Current YoY growth of -36.6% is below this long-term average.
How is EKSO's revenue distributed by segment?
EKSO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.